{"id":970480,"date":"2026-06-04T07:04:31","date_gmt":"2026-06-04T11:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo\/"},"modified":"2026-06-04T07:04:31","modified_gmt":"2026-06-04T11:04:31","slug":"regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo\/","title":{"rendered":"Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO"},"content":{"rendered":"

\nLatest clinical data and research illustrate Regeneron\u2019s advancement of innovative science for diverse and serious diseases with significant unmet needs
\n<\/h2>\n
\n

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026. These include the American Diabetes Association (ADA) 86th Scientific Sessions, June 5-8 in New Orleans, and the Endocrine Society Annual Meeting (ENDO 2026), June 13-16 in Chicago.<\/p>\n

\u201cOur presentations at ADA and ENDO reflect the rapid progress of our diverse pipeline across diseases where we see both significant unmet need and a real opportunity to make a meaningful impact on patients’ lives,\u201d said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine, Regeneron. \u201cAt ADA, we\u2019re advancing the healthcare community\u2019s understanding of how muscle and metabolic health intersect \u2014 an area where Regeneron is uniquely positioned to advance research using innovative approaches. And at ENDO, we\u2019re sharing early insights from a novel program in Graves’ and thyroid eye disease, as well as pivotal Phase 3 results for garetosmab in fibrodysplasia ossificans progressiva, or FOP \u2013 a devastating ultra-rare genetic disorder in which muscles, tendons and ligaments are progressively replaced by bone.<\/p>\n

\n New Research on Muscle Biology and Body Composition in Metabolic Disease\u00a0at ADA<\/strong>
\n
Four abstracts at ADA reflect Regeneron’s investment in understanding and addressing muscle loss across metabolic disease. Three abstracts from the Phase 2 COURAGE trial examine the effects of\u00a0trevogrumab\u00a0(anti-GDF8) on lean mass in people with obesity treated with semaglutide, and an additional abstract will provide early preclinical research on muscle biology.<\/p>\n

\n Novel Ophthalmology Program and Phase 3 FOP Data at ENDO<\/strong>
\n
Regeneron will also present 5 abstracts at ENDO, focused on its expanding ophthalmology pipeline and pivotal Phase 3 clinical data for garetosmab as a treatment for FOP. Specifically, two presentations feature early preclinical data from Regeneron’s investigational antibody program targeting Graves’ disease and thyroid eye disease \u2013 two conditions driven by the same underlying biology that can cause hyperthyroidism and painful eye protrusion. In addition, three presentations from the garetosmab program in FOP will be featured in:<\/p>\n